R&D channel feed

Bat­tling low ex­pec­ta­tions and go­liath ri­vals, Re­gen­eron/Sanofi add pos­i­tive Lib­tayo da­ta in pur­suit of block­buster sta­tus

6 years ago
FDA+

Al­ny­lam, Sarep­ta jump in­to Covid-19 game, as pan­dem­ic rekin­dles an­tivi­ral hopes of RNA-tar­get­ing tech­nol­o­gy

6 years ago
Coronavirus
In Focus

Bio­Marin broad­ens its gene ther­a­py hori­zons with a new R&D al­liance in rare car­dio cas­es

6 years ago
Deals
Cell/Gene Tx

Newron's Mer­ck KGaA-in li­censed com­pound fails Rett Syn­drome study, shares wilt

6 years ago

FDA cheers on Gilead­'s remde­sivir with a snap emer­gency OK, giv­ing bio­phar­ma a shot at re­demp­tion

6 years ago
FDA+
Coronavirus

Tick sali­va-de­rived drug shows promise in mid-stage rare skin dis­ease study

6 years ago

Bris­tol My­ers Squibb gets pri­or­i­ty re­view for AML drug as list of po­ten­tial Cel­gene hits length­ens

6 years ago
FDA+

Com­mer­cial strat­e­gy for Gilead­'s Covid-19 drug-to-be remde­sivir re­mains opaque, as chief O'­Day em­pha­sizes re­spon­si­bil­i­ty

6 years ago
Pharma
FDA+

10X: Mod­er­na cre­ates a bil­lion-dose vac­cine pact in a fren­zied race to beat Covid-19 — glob­al­ly

6 years ago
Coronavirus

Af­ter NIH tri­al, EMA be­gins rolling re­view for remde­sivir, set­ting up po­ten­tial au­tho­riza­tions in US and Eu­rope

6 years ago
FDA+
Coronavirus

Con­gres­sion­al watch­dog ad­vis­es HHS to im­ple­ment 'post-mar­ket­ing' in­cen­tives to ad­dress dwin­dling an­tibi­ot­ic de­vel­op­ment ef­forts

6 years ago

Da­ta on Gilead­'s an­tivi­ral bring hope for first Covid-19 drug ap­proval

6 years ago
Coronavirus

No­var­tis spin­out resTOR­bio re­verse merges with T cell biotech af­ter big PhI­II fail­ure

6 years ago
Cell/Gene Tx

Gilead — Piv­otal Covid-19 study of remde­sivir ‘met its pri­ma­ry end­point,' is emer­gency au­tho­riza­tion next?

6 years ago
Coronavirus

Full steam ahead, Pfiz­er goes bar­gain hunt­ing in an age of coro­n­avirus — with a spe­cial fo­cus on can­cer and rare dis­eases

6 years ago
Bioregnum
Coronavirus

Third Rock-backed star­tup's blood test can sniff out can­cer in pa­tients with no his­to­ry of dis­ease

6 years ago
Financing
Startups

Blue­print stum­bles in PhI­II GIST tri­al, send­ing stock slid­ing, but an­a­lysts preach cau­tion

6 years ago

Gilead fires back in on­go­ing bat­tle with HHS, su­ing the gov­ern­ment for ‘se­cret­ly’ ob­tain­ing patents

6 years ago

Weeks af­ter FDA de­lay, Roche, PTC un­veil an­oth­er batch of pos­i­tive ris­diplam da­ta in se­vere SMA pa­tients

6 years ago
FDA+

#AACR20 roundup: Tecen­triq/Xtan­di com­bo fails to show OS ben­e­fit, halt­ing Roche's PD-L1 push in­to prostate can­cer

6 years ago

An on­col­o­gy up­start with some deep-pock­et VC con­nec­tions has a uni­corn-sized ven­ture round to back the pipeline

6 years ago
Financing
Startups

#AACR20: Ear­ly da­ta sug­gest No­var­tis' In­cyte-dis­cov­ered MET in­hibitor helps lung can­cer pa­tients with brain le­sions

6 years ago

Ax­some shares rock­et up on a sur­prise win for late-stage Alzheimer’s ag­i­ta­tion study — but this is no easy layup

6 years ago

Covid-19 roundup: Sanofi & Re­gen­eron de­liv­er dis­ap­point­ing news on IL-6; Alex Azar ru­mors are swirling at HHS

6 years ago
Coronavirus
First page Previous page 203204205206207208209 Next page Last page
A service from the Financial Times